Thu, Nov 27, 2014, 1:36 PM EST - U.S. Markets closed for Thanksgiving Day


% | $
Quotes you view appear here for quick access.

Dynavax Technologies Corporation Message Board

erniewerner 2 posts  |  Last Activity: Sep 2, 2014 7:29 AM Member since: Jan 18, 2000
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    calling oncodoc02138....

    by semanresu Sep 2, 2014 5:32 AM
    erniewerner erniewerner Sep 2, 2014 7:29 AM Flag

    "While I am disappointed, this merely represents the crazy world of biotech investing. I never invest more than I am willing to lose."

    It's going to be an ugly day. I will not be surprised to see it settle out around $1.50. The Comet result is very much in line with prior results for Nexavar and Sutent, two other dirty VEGF TKI's that failed CRPC trials I think this means that the bone effects of Cabo are fleeting at best and perhaps somewhat illusory. For the near term that leaves the Meteor trial in RCC. With a PFS endpoint, this will hopefully have a better outcome. Cabo demonstrated very good PFS data in the EXAM trial and now again in the Comet trial. To say the least, very disappointing.

  • Reply to

    COMET-1 has 89.8% chances of failing

    by socialdiocies Aug 28, 2014 11:19 AM
    erniewerner erniewerner Aug 31, 2014 6:57 PM Flag

    "Irregardless of the timeline issue..."

    How open are you reconsidering the timeline issue?

15.10+0.72(+5.01%)Nov 26 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.